Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Rayzzeron Mar 19, 2018 12:56pm

85 Views

Post# 27740362

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Buying on the Way Up

The Ulcerative Colitis study list on Topstone's site is sponsored by Ferring Pharmaceuticals not Antibe.
https://clinicaltrials.gov/ct2/show/NCT02522780

Newtothegame86 wrote:

HarveyTwoface wrote: Maybe that's why Topstone are looking for participants to their upcoming Ulcerative Colitis research stydy ? Check it out here

(Just speculation on my side)

I obviously don't know that the ulcerative colitis trial isn't for Antibe, but I think that is something they would have to release to the share holders, or at least want to, given their current financial state.